This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
De Silva CM, Reid R . Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9: 13–19.
Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003; 97: 2760–2766.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
Milojkovic D, Short K, Salisbury JR, Creamer D, du Vivier AWP, Mufti GJ . Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 2003; 17: 1414–1416.
Sarkany RP . The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26: 225–232.
Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M . Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukaemia. J Clin Oncol 1995; 13: 2401–2407.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Breccia, M., Latagliata, R., Carmosino, I. et al. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. Leukemia 18, 182 (2004). https://doi.org/10.1038/sj.leu.2403115
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403115